Table 3.
Treatment comparison on PFS and OS, in subgroup analysis by PD-L1 expression on tumor cells (≥1% cutoff)
| METEOR (N=306) | CABOSUN (N=110) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| CABOZANTINIB (C) |
EVEROLIMUS (E) |
C vs E | CABOZANTINIB (C) |
SUNITINIB (S) |
C vs S | |||||
| N | Median months (95%CI) |
N | Median months (95%CI) |
Hazard ratio (95%CI) |
N | Median months (95%CI) |
N | Median months (95%CI) |
Hazard ratio (95%CI) |
|
| PFS | ||||||||||
| PD-L1(−) | 112 | 8.5 (7.2-13.5) |
106 | 4.1 (3.7-6) |
0.46 (0.32-0.66) |
52 | 11.0 (6.8-15.6) |
33 | 5.0 (3-12.9) |
0.47 (0.26-0.86) |
| PD-L1(+) | 38 | 5.6 (4.5-7.4) |
50 | 3.7 (2-5.3) |
0.66 (0.40-1.11) |
9 | 8.4 (1.1-16.6) |
16 | 3.1 (1.6-10.1) |
0.46 (0.18-1.21) |
| P-interaction | 0.217 | 0.998 | ||||||||
| OS | ||||||||||
| PD-L1(−) | 112 | NR | 106 | 18.4 (15.1-NR) |
0.58 (0.38-0.88) |
52 | 30.3 (18.8-NR) |
33 | 22.4 (7.6-NR) |
0.71 (0.39-1.29) |
| PD-L1(+) | 38 | 18.4 (10.4-22) |
50 | 13.9 (8.7-18.9) |
0.82 (0.47-1.41) |
9 | 18.1 (1.1-35) |
16 | 21.0 (6.4-30.8) |
0.85 (0.31-2.31) |
| P-interaction | 0.359 | 0.372 | ||||||||
PFS: Progression free survival; OS: Overall survival